top of page
< Back

Rosuvastatin

瑞舒伐他汀

Mechanism of action:

Rosuvastatin 是一種 HMG-CoA 還原酶抑制劑（HMG-CoA reductase inhibitor）。Rosuvastatin 會與 HMG-CoA 還原酶結合，抑制其將 HMG-CoA 轉化為甲羥戊酸（mevalonate），降低肝臟內膽固醇生成，使肝細胞內膽固醇濃度下降，之後導致上調肝細胞的 LDL 受體表達，增強血液的低密度脂蛋白膽固醇（LDL-C）的攝取與分解。最終血漿中 LDL-C、總膽固醇、極低密度脂蛋白（VLDL）以及三酸甘油脂可下降，同時高密度脂蛋白膽固醇（HDL-C）可能輕微上升。

​Reference(s):

1. Di Napoli P et al. (2005). Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res. 


2. Everett BM et al. (2010). Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. 


3. Jones SP et al. (2002). Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol.

bottom of page